Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FASN | P49327 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | FAAH | O00519 | 4/20 | 0.51 |
| ▸ | CNR1 | P21554 | 2/20 | 0.50 |
| ▸ | CNR2 | P34972 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL118480 | 1.00 | FASN (0.53) | FASNKDM4EMAPTFAAHCNR1 | |
| SCHEMBL117739 | 1.00 | FASN (0.53) | FASNKDM4EMAPTFAAHCNR1 | |
| SCHEMBL1503636 | 1.00 | FASN (0.53) | FASNKDM4EMAPTFAAHCNR1 | |
| SCHEMBL650656 | 1.00 | FASN (0.53) | FASNKDM4EMAPTFAAHCNR1 | |
| SCHEMBL118129 | 1.00 | FASN (0.53) | FASNKDM4EMAPTFAAHCNR1 | |
| SCHEMBL18297784 | 1.00 | FASN (0.53) | FASNKDM4EMAPTFAAHCNR1 | |
| SCHEMBL23921985 | 1.00 | FASN (0.53) | FASNKDM4EMAPTFAAHCNR1 | |
| SCHEMBL375162 | 1.00 | FASN (0.53) | FASNKDM4EMAPTFAAHCNR1 | |
| SCHEMBL18297783 | 1.00 | FASN (0.53) | FASNKDM4EMAPTFAAHCNR1 | |
| SCHEMBL118128 | 1.00 | FASN (0.53) | FASNKDM4EMAPTFAAHCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115466180-A | Method for purifying eicosapentaenoic acid ethyl ester | 江苏海莱康生物科技有限公司 | 2022-12-13 | — | — | CN | claimed |
| EP-2172225-B1 | SEAMLESS CAPSULE | TAKEDA PHARMACEUTICALS CO (JP) | 2019-08-07 | — | — | EP | disclosed |
| EP-2455071-A1 | Capsule Formulation | Takeda Pharmaceutical Company Limited (JP) | 2012-05-23 | — | — | EP | disclosed |
| EP-2455070-A1 | Capsule Formulation | Takeda Pharmaceutical Company Limited (JP) | 2012-05-23 | — | — | EP | disclosed |
| US-20100285121-A1 | Capsule Formulation | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2010-11-11 | — | — | US | disclosed |
| EP-2229939-A1 | CAPSULE FORMULATION | Takeda Pharmaceutical Company Limited (JP) | 2010-09-22 | — | — | EP | disclosed |
| US-20100119598-A1 | SEAMLESS CAPSULE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-13 | — | — | US | disclosed |
| EP-2172225-A1 | SEALMESS CAPSULE | Takeda Pharmaceutical Company Limited (JP) | 2010-04-07 | — | — | EP | disclosed |
| EP-2150820-A1 | ANALYSIS METHOD | Surescreen Diagnostics Limited (GB) | 2010-02-10 | — | — | EP | disclosed |
| WO-2008122805-A1 | ANALYSIS METHOD | SURESCREEN DIAGNOSTICS LIMITED (GB) | 2008-10-16 | — | — | WO | disclosed |